JAZZ Rises on Updated OS Results From Gastric Cancer Study

Updated HERIZON-GEA-01 results indicate statistically significant overall survival benefits from Ziihera-based first-line regimens in HER2+ gastroesophageal adenocarcinoma. The article frames this as positive clinical readthrough for the regimen’s efficacy, but it provides no specific effect-size (e.g., hazard ratio) or magnitude to gauge economic impact. Likely modest near-term relevance for valuation sentiment unless detailed OS metrics confirm strength.